Lichen planus pigmentosus and association with autoimmune diseases: A case–control study

Monia Youssef¹, Ines Lahouel¹, Mouna Korbi¹, Yosra Soua¹, Hela Marmouch², Hayet Akkari¹, Meriem Mohamed¹, Hichem Belhajali¹, Asma Belghith³, Jameleddine Zili¹

¹Dermatology Department, Fattouma Bourguiba Hospital, University of Monastir, Tunisia, ²Endocrinology Department, Fattouma Bourguiba Hospital, University of Monastir, Tunisia, ³Community Medicine Department, Fattouma Bourguiba Hospital, University of Monastir, Tunisia

Corresponding author: Dr Ines Lahouel, E-mail: lahouel.iness@gmail.com

ABSTRACT

Background: Studies on the co morbidities seen with lichen Planus Pigmentosus (LPP) are limited. Aims: We sought to determine the prevalence of auto immune diseases (AD) associated with LPP. Methods: A total of 30 patients with LPP and 30 age and sex matched controls were examined. Both groups were evaluated for the presence of AD using physical examination and immunological tests. Results: We collected 30 LPP patients. There were 9 men and 21 women. Prevalence of AD was higher in LPP patients (40.0%) than in the control group (3.3%). LPP was significantly associated with AD, the age and gender adjusted OR was 22.9; P: 0.005. Twelve patients had an associated AD. There was no statistically significant difference between the group with ADs and without ADs concerning the sex, the age of onset of the disease, the extent of the lesions and the evolution. The immunological tests were positive in only one patient. Limitations: This study was performed in a little sample with a geographically restricted population. Conclusion: We found a frequent association of LPP with ADs. We suggest that autoimmunity might be a pathogenic factor of LPP.

Key words: Lichen planus pigmentosus; Autoimmune diseases; Case–control study

INTRODUCTION

Lichen planus pigmentosus (LPP) is an uncommon variant of lichen planus (LP), characterized by the insidious onset of dark brown macules in sun-exposed areas and flexural folds with or without slight pruritus [1,2]. It was originally reported from India, but it tends to occur also in other racial and ethnic groups such as Latin Americans, Middle Eastern population, Japanese and Koreans [3-5].

The epidemiologic and physiopathologic characteristics of LPP have not yet been defined. LPP has rarely been described in association with other diseases. The autoimmune pathogenesis of LPP is a controversial subject. No clear association between LPP and auto immune diseases (AD) exists. In our clinical experience, we have observed that patients with LPP often have an AD. A careful review of literature did not find studies that specifically address the prevalence of ADs in patients with LPP. Therefore, we realized this study with a purpose to determine the prevalence of AD in patients with LPP.

MATERIALS AND METHODS

Study Design

A case–control study was performed to assess the prevalence of AD in patients with LPP. The patients and controls were matched on age and sex, and recruited over a 6-year period (2011-2016).

Patients

We aimed to enroll, consecutively, all patients with a diagnosis of LPP who were admitted to the clinics of...
the dermatology department of Monastir hospital in Tunisia.

Inclusion criteria for cases were the presence of largely asymptomatic bluish / blackish brown, macules, distributed mainly on the face, neck and upper extremities. The histological criteria were: (a) epidermal changes: minimal change in epidermal thickness; keratinocyte apoptosis; and vacuolar degeneration of the basal cell layer and (b) dermal changes: presence of band like or perivascular lymphohistiocytic inflammatory infiltrate; scattered melanophages; and melanin incontinence. 30 patients with a diagnosis of LPP were enrolled as the patient group.

Controls

The control group consisted of 30 age and sex matched individuals (Table 1). The controls were selected among patients with skin diseases other than LPP (chronic pruritus with no specific lesions). The source population for cases and controls was the same.

Collection of Data

All cases and controls were examined by a dermatologist who registered demographic, biometric and other relevant data on a case report form.

The age of onset, duration of the disease, site of onset of pigmentation, associated symptoms and family history were recorded.

The information was also obtained regarding any related external factors (such as drug intake prior to the onset or use of cosmetics), associated autoimmune diseases, cutaneous diseases or other systemic diseases.

A record was made for the morphology and distribution of lesions, extent of lesions, and mucosal, hair and nail involvement.

For all patients and controls, laboratory tests were performed including complete blood count (CBC), sedimentation rate (SR), blood sugar test (BS), antinuclear antibodies (ANA), anti thyroglobulin antibodies (TgAb), anti-thyroid peroxidase antibodies (TPOAb) and serology tests for hepatitis B and C.

The age of onset of the disease, the sex, the site of early lesions, the extent of the lesions, the inversus type, were compared between the two groups of LPP patients with and without ADs, in order to establish if there is or not any factors that may influence this association.

Statistical Analysis

Statistical analysis was performed on the Software Statistical Package for the Social Sciences (SPSS 21). For between-group comparisons, the independent samples t-test was used for normally distributed continuous variables and Pearson chi-squared test or Fisher exact test was used for nominal data where appropriate. Multiple logistic regressions were performed to calculate the odds ratio (OR) and 95% confidence interval (CI) after adjusting for age and gender. The statistical significance was fixed with p inferior to 0.05.

RESULTS

The study included 30 cases and 30 controls. For patients, there were 9 men and 21 women (M/F = 0.42) and the average age at onset was 37.6 years (range 6–68 years). There were 3 children (1 aged 6 years, 2 aged 13 years). The duration of the disease ranged from 1 month to 10 years. Six (20%) patients reported mild pruritus. There was no history of previous inflammatory process on the affected areas for all the patients. A causal relationship with drugs, recent sun exposure, cosmetics or trauma were not identified for all patients. Family history of a similar skin disorder was negative in all the 30 patients.

The clinical pattern of pigmentation within LPP patients was mostly diffuse. The face and trunk (Fig. 1) were the commonest sites affected. Inversus type of LPP was seen in seven patients (23.3%) with most of them localized in the axillae (Fig. 2). Mucosal lesion (oral involvement) was noticed in one patient. The palms, soles, scalp and nails were spared in all patients.

Skin biopsies were performed from all the patients. Most of the patients had overlapping features of the two patterns (pattern of inflammatory infiltrate and superficial perivascular pattern), with predominance of one of them. Melanin incontinence and melanophages...
were constant findings in all cases (Fig. 3). Hyperkeratosis was marked in 11 (36.6%).

Prevalence of AD was higher in LPP patients (40.0%) than in the control group (3.3%). LPP was significantly associated with AD, the age and gender adjusted OR was 22.9; CI 95%; 2.62-199.82; P: 0.005 (Table 2).

Twelve patients (40%) with AD were collected. No significant difference was observed in the extent of lesions in groups with and without AD.

Six patients were diabetic (three patients had diabetes type 1 (DT1) and three patients had Latent Autoimmune Diabetes in Adults (LADA). Three patients had chronic inflammatory bowel diseases (one patient had Crohn’s disease, one patient had ulcerative colitis and one patient had lymphocytic colitis). The patient who had lymphocytic colitis had also hypothyroidism. One patient had rheumatoid arthritis, one patient had anti phospholipid antibody syndrome and one patient had Gougerot Sjogren syndrome.

The diagnosis of AD preceded LPP in 9 cases, was made simultaneously with LPP in 2 patients (LADA, autoimmune thyroiditis). One patient developed LADA one year after the diagnosis of LPP.

For all patients the CBC, SR were within normal limits. Hepatitis B and C serology tests were negative for all patients.

The recommended immunological tests were positive in only one patient, who had rheumatoid arthritis. In fact, ANA, anti-nucleosome antibodies, anti TgAb and anti TPO Ab were significantly positive (TPOAb=93UI/ml, Tg Ab=390UI/ml, ANA=1/800, anti nucleosome Ab=222 UI/ml) while the patient was asymptomatic and had no previous history for lupus nor dysthyroidism.

There were no significant differences regarding the serum levels of CBC, SR, ANA, TgAb, TPOAb and Hepatitis B and C serology tests between cases and controls (P = 1, 049, 1, 1 and 1 respectively).

The results of the characteristics of patients with AD are summarized in Table 3.

<table>
<thead>
<tr>
<th>Association with AD</th>
<th>Positive</th>
<th>Negative</th>
<th>p</th>
<th>ORa*</th>
<th>CI 95% (ORa)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases</td>
<td>12 (40%)</td>
<td>18 (60%)</td>
<td>0.005</td>
<td>22.86</td>
<td>2.63-199.83</td>
</tr>
<tr>
<td>Controls</td>
<td>1 (3.3%)</td>
<td>29 (96.7%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ORa*: Age and sexe adjusted OR
DISCUSSION

Our study is a pilot study and the first study from Tunisia seeking for LPP associated diseases. Our results were in agreement with previous studies from Japan, India and Kuwait regarding the clinico-epidemiologic aspects of LPP [3-6]. Nevertheless, we report a significant association between LPP and ADs (more than the quarter of our patients had associated ADs). This association has not been reported before. Analysis of the prevalence of ADs in patients with or without LPP and possible associated risk factors, particularly sex, age, site of early lesions, extent of lesions, itching and the course after topical corticosteroid, did not show statistically significant differences.

Although the association between LP and ADs is well known, a similar prevalence in LPP patients has not been established. In fact, an Italian epidemiologic study had reported data supporting the association between LP and alopecia areata and ulcerative colitis, which are considered immune-mediated diseases [7]. A significant association between oral lichen planus (OLP) and thyroid gland disease specifically with hypothyroidism had been reported [8]. It had also been reported that, in Chinese patients with OLP, 21% have TgAb and 24% have TMA autoantibodies compared with 1.9% of healthy control subjects [9].

Recently, Chung PI et al [10] reported a significant association with systemic lupus erythematosus, Sjögren’s syndrome, dermatomyositis, vitiligo and alopecia areata among patients with LP.

A case of LPP associated with minimal change nephrotic syndrome have been reported [11]. Authors suggested that this association may reflect common immunological abnormalities. Otherwise, three cases of frontal fibrosing alopecia associated to LPP have been reported [12-14].

In our study, auto-immune diabetes was the most frequent AD associated to LPP (20%). The association between LPP and diabetes had not been reported before. However, the relationship between LP and diabetes was studied previously. A study concerning the prevalence of OLP in diabetes mellitus according to the type of diabetes [15], found that the prevalence

<table>
<thead>
<tr>
<th>Sex/age</th>
<th>Duration</th>
<th>Associated AD</th>
<th>Site</th>
<th>Histological examination</th>
<th>Treatment</th>
<th>Course</th>
</tr>
</thead>
<tbody>
<tr>
<td>F/29</td>
<td>3 months</td>
<td>DT 1</td>
<td>Thigh</td>
<td>Pervascular lymphohistiocytic infiltrate, pigmentary incontinence, keratinocyte necrosis</td>
<td>Topical betamethasone</td>
<td>No improvement</td>
</tr>
<tr>
<td>M/36</td>
<td>2 months</td>
<td>DT 1</td>
<td>Face, axillary folds</td>
<td>Hypergranulosis, melanin incontinence, perivascular lymphohistiocytic infiltrate</td>
<td>Topical betamethasone</td>
<td>Aggravation</td>
</tr>
<tr>
<td>F/54</td>
<td>4 months</td>
<td>LADA</td>
<td>Face, abdomen, axillary folds</td>
<td>Hyperkeratosis, hypergranulosis, Band-like lymphocytic infiltrate</td>
<td>Topical betamethasone</td>
<td>No improvement</td>
</tr>
<tr>
<td>F/62</td>
<td>3 months</td>
<td>LADA</td>
<td>Back, Upper and lower limbs</td>
<td>Thinning of the epidermis, hyperkeratosis, pigmentary incontinence, perivascular lymphohistiocytic infiltrate</td>
<td>Topical betamethasone</td>
<td>No improvement</td>
</tr>
<tr>
<td>F/56</td>
<td>2 months</td>
<td>LADA</td>
<td>Back</td>
<td>Hyperkeratosis, pigmentary incontinence, melanophages</td>
<td>Topical betamethasone</td>
<td>No improvement</td>
</tr>
<tr>
<td>F/30</td>
<td>4 months</td>
<td>D T 1</td>
<td>Lower limbs</td>
<td>Hypergranulosis, Band-like lymphocytic infiltrate, pigmentary incontinence</td>
<td>Topical betamethasone</td>
<td>No improvement</td>
</tr>
<tr>
<td>M/30</td>
<td>4 months</td>
<td>Lymphocytic colitis-hypothyroidism</td>
<td>Trunk</td>
<td>Hyperkeratosis, hypergranulosis, Band-like lymphocytic infiltrate, pigmentary incontinence</td>
<td>Topical betamethasone</td>
<td>Slight improvement</td>
</tr>
<tr>
<td>F/31</td>
<td>6 months</td>
<td>SAPL</td>
<td>Back</td>
<td>Hyperkeratosis, pigmentary incontinence, lymphohistiocytic infiltrate, melanophages</td>
<td>Topical betamethasone</td>
<td>Slight improvement</td>
</tr>
<tr>
<td>F/68</td>
<td>6 months</td>
<td>Rheumatoid arthritis</td>
<td>Back, upper and lower limbs</td>
<td>Hyperkeratosis, hypergranulosis band-like lymphocytic infiltrate and melanophagia in the papillary dermis</td>
<td>Topical betamethasone</td>
<td>No improvement</td>
</tr>
<tr>
<td>F/37</td>
<td>1 year</td>
<td>Gougerot Sjogren syndrome</td>
<td>Lower members, axillary folds</td>
<td>Lichenoid dermatitis, pigmentary incontinence</td>
<td>Topical betamethasone</td>
<td>No improvement</td>
</tr>
<tr>
<td>M/52</td>
<td>3 months</td>
<td>Crohn’s disease</td>
<td>Face</td>
<td>Hyperkeratosis, pigmentary incontinence, lymphohistiocytic infiltrate, melanophages</td>
<td>Topical betamethasone</td>
<td>Slight improvement</td>
</tr>
<tr>
<td>F/42</td>
<td>8 months</td>
<td>Ulcerative colitis</td>
<td>Face, upper and lower limbs</td>
<td>Keratinocyte necrosis, melanin incontinence, perivascular lymphohistiocytic infiltrate, melanophages</td>
<td>Topical betamethasone</td>
<td>Slight improvement</td>
</tr>
</tbody>
</table>
of OLP in type 1 diabetic patients was 5.76%, in type 2, 2.83%, and 1.82% in the controls. Giving the fact that DT 1 and OLP are characterized with autoimmune phenomena and T cell immune responses respectively, the authors suggested that the immune system may play a role in the appearance of OLP in patients with DT1.

We suggest that immunological mechanisms mediate the pathogenesis of LPP, as evidenced by association with diseases of altered immunity.

We didn’t found studies seeking for the association between LPP and AD but we found a study published recently looking for the association between LPP and thyroid dysfunction [16]. Thyroid disorder was found to be an associated factor in LPP especially hypothyroidism. Levels of thyroid peroxidase antibody in the LPP patients were found to be significantly higher than those of controls. These results support our hypothesis concerning the autoimmune pathogenesis of LPP.

Otherwise, LPP have been reported associated with a non AD which is Hepatitis C. In fact, in the study of Al-Mutairi, 60.6% of patients with LPP had positive hepatitis C serology tests. These patients had significantly elevated serum ALT and AST levels, and they were also significantly of older age group and their skin disease was of longer duration compared with patients with negative serology for HCV. In our study, serology tests for Hepatitis B and C were negative for all patients.

**Limitations**

Because of the rarity of LPP, and that this study was done in a geographically restricted population, other studies with larger sample sizes from different parts of the world are needed to add further evidence for this association of LPP and AD.

**CONCLUSION**

As it has been shown in our study, there is an increased risk multiplied by 22.8 for patients with AD to develop LPP. Patients with LPP are at increased risk of multiple co morbidities such as auto immune diabetes, chronic inflammatory bowel diseases, hypothyroidism, rheumatoid arthritis, anti phospholipid antibody syndrome and Gougerot Sjogren syndrome, which support the key role of autoimmunity in the pathogenesis of LPP. Further researches are required to elucidate the underlying mechanism of the association of these autoimmune co morbid diseases with LPP. Regarding our findings, immunological tests in patients with LPP are required, especially if an AD is suspected based upon a review of symptoms. We suggest also that LPP patients should be supervised because they could develop AD.

**Statement of Human and Animal Rights**

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

**Statement of Informed Consent**

Informed consent was obtained from all patients for being included in the study.

**REFERENCES**